DDInter1840 DDInter299
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
Trabectedin {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Carfilzomib
Trabectedin {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Ritonavir
Ritonavir {u} (Compound) resembles {v} (Compound) Carfilzomib
Trabectedin {u} (Compound) causes {v} (Side Effect) Infection
Infection {u} (Side Effect) is caused by {v} (Compound) Cabazitaxel
Cabazitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carfilzomib
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) interacts with {v} (Gene) PSMB9
PSMB9 {u} (Gene) is bound by {v} (Compound) Carfilzomib
Trabectedin {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Bedaquiline
Bedaquiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carfilzomib
Trabectedin {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Zafirlukast
Zafirlukast {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carfilzomib
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carfilzomib
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carfilzomib
Trabectedin {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Ritonavir
Ritonavir {u} (Compound) resembles {v} (Compound) Carfilzomib
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is upregulated by {v} (Compound) Dapsone
Dapsone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carfilzomib
Trabectedin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Carfilzomib (Compound)
Trabectedin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ritonavir (Compound) and Ritonavir (Compound) resembles Carfilzomib (Compound)
Trabectedin (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Cabazitaxel (Compound) and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) interacts with PSMB9 (Gene) and PSMB9 (Gene) is bound by Carfilzomib (Compound)
Trabectedin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Bedaquiline (Compound) and Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Trabectedin (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Zafirlukast (Compound) and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is bound by Crizotinib (Compound) and SRC (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is bound by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Trabectedin (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Ritonavir (Compound) and Ritonavir (Compound) resembles Carfilzomib (Compound)
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is upregulated by Dapsone (Compound) and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib